

SCORE Search Results Details for Application 10531543 and Search Result 20081031_131728_us-10-531-543-1.rng.

Score Home Page	Retrieve Application List	SCORE System Overview	SCORE FAQ	Comments / Suggestions
---------------------------------	---	---------------------------------------	---------------------------	--

This page gives you Search Results detail for the Application 10531543 and Search Result 20081031_131728_us-10-531-543-1.rng.

[Go Back to previous page](#)

GenCore version 6.3
Copyright (c) 1993 - 2008 Biocceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: October 31, 2008, 16:58:58 ; Search time 455 Seconds
(without alignments)
39457.692 Million cell updates/sec

Title: US-10-531-543-1

Perfect score: 1262

Sequence: 1 ctgggtggggaaagggtccaaag.....tgaaaaaaaaaaaaaaaaaa 1262

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 11806651 seqs, 7113014948 residues

Total number of hits satisfying chosen parameters: 23613302

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_200808:*

1: geneseqn1980s:*

2: geneseqn1990s:*

3: geneseqn2000:*

4: geneseqn2001a:*

5: geneseqn2001b:*

6: geneseqn2002a:*

7: geneseqn2002b:*

```

8:  geneseqn2003a:*
9:  geneseqn2003b:*
10:  geneseqn2003c:*
11:  geneseqn2003d:*
12:  geneseqn2004a:*
13:  geneseqn2004b:*
14:  geneseqn2004c:*
15:  geneseqn2004d:*
16:  geneseqn2004e:*
17:  geneseqn2004f:*
18:  geneseqn2005a:*
19:  geneseqn2005b:*
20:  geneseqn2005c:*
21:  geneseqn2006a:*
22:  geneseqn2006b:*
23:  geneseqn2006c:*
24:  geneseqn2006d:*
25:  geneseqn2007a:*
26:  geneseqn2007b:*
27:  geneseqn2007c:*
28:  geneseqn2007d:*
29:  geneseqn2008:*

```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%

Result No.	Score	Query					Description
		Match	Length	DB	ID		
1	1262	100.0	1262	21	AEG21170		Aeg21170 Human Jab
2	1262	100.0	1262	21	AFS77968		Afs77968 Human Jun
3	1260	99.8	1282	29	AOF63552		Aof63552 Mouse Kip
4	966.8	76.6	1288	18	ADY80674		Ady80674 Human JAB
5	966.8	76.6	1288	18	ADY80675		Ady80675 Human JAB
6	966.8	76.6	1309	18	ADY80676		Ady80676 Human JAB
7	966.8	76.6	1510	18	ADY80669		Ady80669 Human JAB
8	959.4	76.0	1292	10	ADI31651		Adi31651 Human cDN
9	959.4	76.0	1292	12	ADS83718		Ads83718 Human lym
10	959.4	76.0	1292	18	ADY80668		Ady80668 Human JAB
11	948.8	75.2	1277	9	ADF81512		Adf81512 Leukaemia
12	948.8	75.2	1277	12	ACN38816		Acn38816 Tumour-as
13	948.8	75.2	1277	20	AFU76250		Afu76250 Human pro
14	948.8	75.2	1277	20	AFU81485		Afu81485 Human pro
15	948.4	75.2	1287	6	AAD24415		Aad24415 Human RNA
16	936.8	74.2	1433	13	ADP56481		Adp56481 Human bre
17	881.6	69.9	981	2	AAT32620		Aat32620 pACT59 co

18	881.6	69.9	981	3	AAA94275	Aaa94275 Murine T
19	874	69.3	1263	9	ADA53665	Ada53665 Human cod
20	823.2	65.2	949	6	ABS51512	Abs51512 Human cDN
21	797.6	63.2	919	2	AAT32621	Aat32621 pACT74 co
22	797.6	63.2	919	3	AAA94276	Aaa94276 Murine T
23	791.2	62.7	1262	13	ADP56483	Adp56483 Human bre
24	791.2	62.7	1937	13	ADP56482	Adp56482 Human bre
25	790.6	62.6	3479	13	ADR08249	Adr08249 Full leng
26	753.2	59.7	871	6	ABS51518	Abs51518 Human cDN
27	750.2	59.4	868	8	ACA57249	Aca57249 Human adi
28	697.8	55.3	1661	27	ARB60069	Arb60069 DNA fragm
29	674.2	53.4	1059	27	ARB75265	Arb75265 DNA fragm
30	674.2	53.4	1729	6	ABZ78075	Abz78075 Human bre
31	669.8	53.1	777	8	ACA57301	Aca57301 Human adi
32	590.4	46.8	680	8	ACA57034	Aca57034 Human adi
33	570.6	45.2	657	8	ACA57385	Aca57385 Human adi
34	567.6	45.0	654	8	ACA57045	Aca57045 Human adi
35	560.4	44.4	642	6	ABS51593	Abs51593 Human cDN
36	554.4	43.9	636	8	ACA57112	Aca57112 Human adi
37	534.4	42.3	757	27	ARB73520	Arb73520 DNA fragm
38	509.8	40.4	585	6	ABS51610	Abs51610 Human cDN
39	495	39.2	579	19	AEE12148	Aee12148 Hamster c
40	495	39.2	579	19	AEE15790	Aee15790 Hamster S
41	475.6	37.7	1314	13	ADP56484	Adp56484 Human bre
42	475	37.6	562	6	ABK39139	Abk39139 cDNA enco
43	475	37.6	562	8	ACA02654	Aca02654 Lung canc
44	475	37.6	562	8	ACA11468	Aca11468 Human lun
45	475	37.6	562	9	ADH46696	Adh46696 Human lun

ALIGNMENTS

RESULT 1

AEG21170

ID AEG21170 standard; DNA; 1262 BP.

XX

AC AEG21170;

XX

DT 04-MAY-2006 (first entry)

XX

DE Human Jab1 DNA.

XX

KW gene; ds; flavivirus infection; pestivirus infection; infection;

KW Jun-activation binding protein 1; West nile virus infection;

KW neurological disease; temperature disorder; fever;

KW cardiovascular disease; bleeding; jaundice; gastrointestinal disease;

KW metabolic disorder; arthralgia; myalgia; musculoskeletal disease;

KW encephalitis; meningitis; Virucide; Antipyretic; Antiinflammatory;

KW Antiallergic; Hemostatic; Hepatotropic; apoptosis inhibitor.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT CDS 94. .1098

FT /*tag= a

FT /product= "Jab1"

XX

PN WO2006025623-A1.

XX

PD 09-MAR-2006.

XX

PF 31-AUG-2004; 2004WO-KR002190.

XX

PR 31-AUG-2004; 2004WO-KR002190.

XX

PA (UYSU-) UNIV SUNGKYUNKWAN.

XX

PI Song J, Oh W, Pyo SN, Yang J, Lee H, Lee SR, Sung YH;

XX

DR WPI; 2006-204334/21.

DR P-PSDB; AEG21171.

XX

PT New composition comprising a Jab1 (Jun-activation binding protein 1) protein or the nucleic acid sequence encoding the protein, useful for treating or preventing a flavivirus or pestivirus infection, e.g. fever, rash, meningitis.

XX

PS Claim 3; SEQ ID NO 1; 72pp; English.

XX

CC This invention describes a novel composition for treating or preventing a flavivirus or pestivirus infection, comprising a Jab1 (Jun-activation binding protein 1) protein AEG21171 or the nucleic acid sequence encoding the protein, AEG21170. The invention also describes; a) a method of screening a compound stimulating expression of a Jab1 protein, comprising culturing a cell expressing the Jab1 protein, contacting the cultured cell with candidate compounds for stimulating expression of the Jab1 protein, comparing an expression level of the Jab1 protein with that in a control not contacted with the candidate compounds and identifying a compound increasing expression levels of the Jab1 protein and b) a method of screening a compound stimulating interaction between a Jab1 protein and a capsid (Cp) protein, comprising culturing a cell transformed with both a recombinant vector expressing the Jab1 protein and another recombinant vector expressing the Cp protein of flavivirus or pestivirus, contacting the cultured cell with candidate compounds for stimulating interaction between the Jab1 protein and the Cp protein, comparing an expression level of the Cp protein with that in a control not contacted with the candidate compounds and identifying a compound reducing

CC expression levels of the Cp protein. The Jab1 nucleic acid AEG21170 can
 CC be incorporated into a recombinant viral vector selected from recombinant
 CC retrovirus, adenovirus, adeno-associated virus and herpes simplex virus.
 CC The composition of the invention is particularly effective for treating
 CC flavivirus infection e.g. West Nile virus which causes fever, rash,
 CC bleeding, jaundice, arthralgia, myalgia, encephalitis or meningitis. This
 CC sequence encodes the human Jab1 protein. The Jab1 protein is found to
 CC interact with the capsid protein of flavivirus and inhibits apoptosis by
 CC accelerating the degradation of the capsid protein.

XX

SQ Sequence 1262 BP; 394 A; 265 C; 302 G; 301 T; 0 U; 0 Other;

Query Match 100.0%; Score 1262; DB 21; Length 1262;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTGGTGGGGAAAGGTCCAAAGCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA 60
 |||||||

Db 1 CTGGTGGGGAAAGGTCCAAAGCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA 60

Qy 61 TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTCCGGAGTGGTATGCC 120
 |||||||

Db 61 TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTCCGGAGTGGTATGCC 120

Qy 121 CAGAAAACCTGGGAATTGCCAACACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC 180
 |||||||

Db 121 CAGAAAACCTGGGAATTGCCAACACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC 180

Qy 181 AAATATGACAAAAAACAAACAAGAAATCCTGGCGCGAAACCCTGGACTAAGGATCAC 240
 |||||||

Db 181 AAATATGACAAAAAACAAACAAGAAATCCTGGCGCGAAACCCTGGACTAAGGATCAC 240

Qy 241 CACTACTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTATGCATGCC 300
 |||||||

Db 241 CACTACTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTATGCATGCC 300

Qy 301 AGGTCAAGGAGGCAACTTGGAAAGTGTGGTTGATGCTCGGAAAGTCGACGGCGAGACC 360
 |||||||

Db 301 AGGTCAAGGAGGCAACTTGGAAAGTGTGGTTGATGCTCGGAAAGTCGACGGCGAGACC 360

Qy 361 ATGATCATCATGGACAGTTCGCTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT 420
 |||||||

Db 361 ATGATCATCATGGACAGTTCGCTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT 420

Qy 421 CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAACAGGTTGGCCGC 480
 |||||||

Db 421 CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAACAGGTTGGCCGC 480

Qy 481 CTTGAGAATGCAATCGGTTGGTATCATAGCCACCCCTGGTTGGCTGGCTCTCCGGG 540

Db 481 CTTGAGAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG 540
Qy 541 ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTCAAGAACCATTTGTTAGCAGTGGTG 600
Db 541 ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTCAAGAACCATTTGTTAGCAGTGGTG 600
Qy 601 ATTGATCCAACCAGAACAAATCTCTGCAGGAAAAGTGAATCTGGCGCCTTAGGACATAT 660
Db 601 ATTGATCCAACCAGAACAAATCTCTGCAGGAAAAGTGAATCTGGCGCCTTAGGACATAT 660
Qy 661 CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAAGACTATCCCACTTAAT 720
Db 661 CCAAAGGGCTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAAGACTATCCCACTTAAT 720
Qy 721 AAAATAGAAGATTTGGCGTGCAC TGCAAACAATATTATGCCTTAGAAGTCTCATATTTC 780
Db 721 AAAATAGAAGATTTGGCGTGCAC TGCAAACAATATTATGCCTTAGAAGTCTCATATTTC 780
Qy 781 AAATCATCTTGGATCGTAAACTACTTGAGCCTTGTGGAATAAAACTGGGTGAATACC 840
Db 781 AAATCATCTTGGATCGTAAACTACTTGAGCCTTGTGGAATAAAACTGGGTGAATACC 840
Qy 841 CTGAGTTCCCTAGCTGTTACTAATGCAGACTACACCACAGGCCAGGTGTTGATTG 900
Db 841 CTGAGTTCCCTAGCTGTTACTAATGCAGACTACACCACAGGCCAGGTGTTGATTG 900
Qy 901 TCTGAGAAGTTAGAGCAGTCGGAAGCCCAACTGGACGTGGCAGTTCATGTTGGCTTA 960
Db 901 TCTGAGAAGTTAGAGCAGTCGGAAGCCCAACTGGACGTGGCAGTTCATGTTGGCTTA 960
Qy 961 GAAACACATGACCGCAAGTCGGAAGACAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA 1020
Db 961 GAAACACATGACCGCAAGTCGGAAGACAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA 1020
Qy 1021 ACCACCATAGAACGCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAAACTGTTAAT 1080
Db 1021 ACCACCATAGAACGCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAAACTGTTAAT 1080
Qy 1081 CAGATTAACGTTGCTTAGTTACCAAGTACTTCTCAAAGCTGGTGTGGAAAGGAAAAA 1140
Db 1081 CAGATTAACGTTGCTTAGTTACCAAGTACTTCTCAAAGCTGGTGTGGAAAGGAAAAA 1140
Qy 1141 GAAGCTCAAGTAACACTTTAACCCAGTTACCAAAACTCAGATTAGAAGACTAAGGTGCT 1200
Db 1141 GAAGCTCAAGTAACACTTTAACCCAGTTACCAAAACTCAGATTAGAAGACTAAGGTGCT 1200
Qy 1201 GTGTGGTGTCTGAGTATTAGCACTGTAATAAAACTATCACGTGAAAAAAAAAAAAAAA 1260

Db 1201 GTGTGGTGTCTGAGTATTAGCACTGTAATAAAACTATCACGTGAAAAAAAAAAAAAA 1260
Qy 1261 AA 1262
||
Db 1261 AA 1262

RESULT 2

AFS77968

ID AFS77968 standard; DNA; 1262 BP.

XX

AC AFS77968;

XX

DT 14-JUN-2007 (first entry)

XX

DE Human Jun-activation binding protein 1 gene, SEQ ID NO: 1.

XX

KW gene; ds; Jab1; Jun-activation binding protein 1; apoptosis inhibition;

KW flavivirus infection; gene therapy; protein degradation; capsid;

KW pestivirus infection.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT CDS 94. .1098

FT /*tag= a

FT /product= "Human Jun-activation binding protein 1"

XX

PN KR2006020531-A.

XX

PD 06-MAR-2006.

XX

PF 31-AUG-2004; 2004KR-00069381.

XX

PR 31-AUG-2004; 2004KR-00069381.

XX

PA (UYSU-) UNIV SUNGKYUNKWAN.

XX

PI Song JW, Oh WK, Sung YH, Lee SR, Lee HW, Pyo SN, Yang JS;

XX

DR WPI; 2006-764085/78.

DR P-PSDB; AFS77969.

XX

PT Composition for treating virus infection diseases comprising jab1
PT inhibiting apoptosis by promotion of decomposition of capsid proteins.

XX

PS Claim 2; SEQ ID NO 1; 26pp; Korean.

XX

CC The invention relates to a composition for treating viral infections

CC comprising a recombinant vector comprising a Jab1 (Jun-activation binding protein 1) DNA for inhibiting apoptosis by promoting the decomposition of capsid proteins, useful for treating diseases caused by infection by a flavivirus or a pestivirus such as pyrexia, eruption, hemorrhage, jaundice, arthralgia, encephalitis or meningitis. The recombinant vector of the invention is a recombinant virus vector selected from a recombinant retrovirus, adenovirus, adeno-associated virus and Herpes simplex virus. The present sequence encodes the human Jab1 polypeptide of the current invention.

XX

SQ Sequence 1262 BP; 394 A; 265 C; 302 G; 301 T; 0 U; 0 Other;

Query Match 100.0%; Score 1262; DB 21; Length 1262;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1262; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTGGTGGGGAAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA 60
 |||||||

Db 1 CTGGTGGGGAAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA 60

Qy 61 TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTTCCGGAGTGGTATGCC 120
 |||||||

Db 61 TTGTGGAGCGACAGCTTCTCCGGTGCCTCGGCCATGGCAGCTTCCGGAGTGGTATGCC 120

Qy 121 CAGAAAACCTGGGAATTGCCAACACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC 180
 |||||||

Db 121 CAGAAAACCTGGGAATTGCCAACACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC 180

Qy 181 AAATATGACAAAAAACAAACAAGAAATCCTGGCGCGAAACCTGGACTAAGGATCAC 240
 |||||||

Db 181 AAATATGACAAAAAACAAACAAGAAATCCTGGCGCGAAACCTGGACTAAGGATCAC 240

Qy 241 CACTACTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTATGCATGCC 300
 |||||||

Db 241 CACTACTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTATGCATGCC 300

Qy 301 AGGTCAAGGAGGCAACTTGGAAAGTGTGGTTGATGCTCGGAAAGTCGACGGCGAGACC 360
 |||||||

Db 301 AGGTCAAGGAGGCAACTTGGAAAGTGTGGTTGATGCTCGGAAAGTCGACGGCGAGACC 360

Qy 361 ATGATCATCATGGACAGTTCGCTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT 420
 |||||||

Db 361 ATGATCATCATGGACAGTTCGCTTGCCTGTAGAGGGCACAGAAACTCGAGTAAATGCT 420

Qy 421 CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAACAGGTTGGCCGC 480
 |||||||

Db 421 CAAGCTGCTGCGTATGAGTATATGGCTGCATACATAGAAAATGCCAACAGGTTGGCCGC 480

Qy 481 CTTGAGAATGCAATCGGTTGGTATCATAGCCACCCCTGGTTGGCTGGCTCTCCGGG 540

Db 481 CTTGAGAATGCAATCGGTTGGTATCATAGCCACCCTGGTTATGGCTGCTGGCTCTCCGGG 540
Qy 541 ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTCAAGAACCATTTGTTAGCAGTGGTG 600
Db 541 ATTGATGTTAGTACACAGATGCTGAACCAGCAGTTCAAGAACCATTTGTTAGCAGTGGTG 600
Qy 601 ATTGATCCAACCAGAACAAATCTCTGCAGGAAAAGTGAATCTGGCGCCTTAGGACATAT 660
Db 601 ATTGATCCAACCAGAACAAATCTCTGCAGGAAAAGTGAATCTGGCGCCTTAGGACATAT 660
Qy 661 CCAAAGGGTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAAGACTATCCCACTTAAT 720
Db 661 CCAAAGGGTACAAACCTCCTGATGAAGGACCTTCTGAGTACCAAGACTATCCCACTTAAT 720
Qy 721 AAAATAGAAGATTTGGCGTGCAC TGCAAACAATATTATGCCTTAGAAGTCTCATATTTC 780
Db 721 AAAATAGAAGATTTGGCGTGCAC TGCAAACAATATTATGCCTTAGAAGTCTCATATTTC 780
Qy 781 AAATCATCTTGGATCGTAAACTACTTGAGCCTTGTGGAATAAAACTGGGTGAATACC 840
Db 781 AAATCATCTTGGATCGTAAACTACTTGAGCCTTGTGGAATAAAACTGGGTGAATACC 840
Qy 841 CTGAGTTCCCTAGCTGTTACTAATGCAGACTACACCACAGGCCAGGTGTTGATTG 900
Db 841 CTGAGTTCCCTAGCTGTTACTAATGCAGACTACACCACAGGCCAGGTGTTGATTG 900
Qy 901 TCTGAGAAGTTAGAGCAGTCGGAAGCCCAACTGGACGTGGCAGTTCATGTTGGCTTA 960
Db 901 TCTGAGAAGTTAGAGCAGTCGGAAGCCCAACTGGACGTGGCAGTTCATGTTGGCTTA 960
Qy 961 GAAACACATGACCGCAAGTCGGAAGACAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA 1020
Db 961 GAAACACATGACCGCAAGTCGGAAGACAAACTTGCCAAAGCTACTAGAGACAGCTGTAAA 1020
Qy 1021 ACCACCATAGAACGCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAAACTGTTAAT 1080
Db 1021 ACCACCATAGAACGCATCCATGGACTGATGTCTCAGGTTATTAAGGATAAAACTGTTAAT 1080
Qy 1081 CAGATTAACGTTGCTTAGTTACCAAGTACTTCTCAAAGCTGGTGTGGAAAGGAAAAA 1140
Db 1081 CAGATTAACGTTGCTTAGTTACCAAGTACTTCTCAAAGCTGGTGTGGAAAGGAAAAA 1140
Qy 1141 GAAGCTCAAGTAACACTTTAACCCAGTTACCAAAACTCAGATTAGAAGACTAAGGTGCT 1200
Db 1141 GAAGCTCAAGTAACACTTTAACCCAGTTACCAAAACTCAGATTAGAAGACTAAGGTGCT 1200
Qy 1201 GTGTGGTGTCTGAGTATTAGCACTGTAATAAAACTATCACGTGAAAAAAAAAAAAAAA 1260

Db 1201 GTGTGGTGTCTGAGTATTAGCACTGTAATAAAACTATCACGTGAAAAAAAAAAAAAA 1260
Qy 1261 AA 1262
||
Db 1261 AA 1262

RESULT 3

AOF63552

ID AOF63552 standard; DNA; 1282 BP.

XX

AC AOF63552;

XX

DT 15-MAY-2008 (first entry)

XX

DE Mouse Kip1 C-terminus interacting protein-2 coding sequence, SEQ ID 1.

XX

KW drug screening; cancer; leukemia; stem cell;

KW Kip1 C-terminus interacting protein-2; Kic2; ds; gene.

XX

OS Mus musculus.

XX

FH Key Location/Qualifiers

FT CDS 116. .1120

FT /*tag= a

FT /product= "Kip1 C-terminus interacting protein-2"

XX

PN JP2007330205-A.

XX

PD 27-DEC-2007.

XX

PF 16-JUN-2006; 2006JP-00168160.

XX

PR 16-JUN-2006; 2006JP-00168160.

XX

PA (UYNA-) UNIV NARA.

XX

PI Kato J;

XX

DR WPI; 2008-E37671/30.

DR P-PSDB; AOF63555.

DR GENBANK; AF068223.

DR PC:NCBI; gi7380922.

DR PC_ENCPRO:NCBI; gi7380923.

XX

PT Preparation of cancer stem cell useful in screening antileukemic agents, involves raising leukemia spontaneous transgenic non-human animal over expressing Jab1 gene, and obtaining cancer stem cell from raised animal.

XX

PS Example 1; SEQ ID NO 1; 22pp; Japanese.

XX

CC The present invention relates to a method of producing cancer stem cell.
 CC The method involves raising leukemia spontaneous transgenic animal
 CC capable of over expressing Jab1 gene, and obtaining cancer stem cell from
 CC the raised animal. The present invention also provides a method for
 CC screening antileukemic agents comprises contacting the cancer stem cell
 CC with test substance; measuring the Jab1 expression level of cancer stem cell
 CC cell, stem cell activity or survival rate of cancer stem cell; comparing
 CC the measured parameters with Jab1 expression level, stem cell activity or
 CC survival rate of control (cancer stem cell not contacted with test
 CC substance); and selecting the test substance as therapeutic agent of
 CC leukemia. Also described is: method of evaluating leukemia therapeutic
 CC effect of test drug with respect to target stem cell. The method of the
 CC invention enables the abundant production of cancer stem cells using
 CC transgenic animal and useful in screening therapeutic and/or preventive
 CC agent of leukemia, evaluating drug efficacy and in elucidating cancer
 CC onset mechanism. The present sequence is a mouse Kip1 C-terminus
 CC interacting protein-2 (Kic2) coding sequence similar to Homo sapiens Jun
 CC activation domain binding protein (Jab1) of the invention.

CC

CC Revised record issued on 29-JAN-2008 : Enhanced with precomputed
 CC information from BOND.

XX

SQ Sequence 1282 BP; 396 A; 268 C; 311 G; 307 T; 0 U; 0 Other;

Query Match 99.8%; Score 1260; DB 29; Length 1282;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1260; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CTGGTGGGGAAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA 60
 |||||||

Db 23 CTGGTGGGGAAAGGTCCAAAGCCCGCACGCTGAGGCCAGTAGAAGAAAGTTGCATCTTGA 82

Qy 61 TTGTGGAGCGACAGCTTCTCGGTGCCTCGGCCATGGCAGCTCCGGAGTGGTATGGCC 120
 |||||||

Db 83 TTGTGGAGCGACAGCTTCTCGGTGCCTCGGCCATGGCAGCTCCGGAGTGGTATGGCC 142

Qy 121 CAGAAAACCTGGATTGCCAACACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC 180
 |||||||

Db 143 CAGAAAACCTGGATTGCCAACACATGCAGGAAGCGCAGAGTATCGATGAAATCTAC 202

Qy 181 AAATATGACAAAAAACAAACAAGAAATCCTGGCGCGAAACCTGGACTAAGGATCAC 240
 |||||||

Db 203 AAATATGACAAAAAACAAACAAGAAATCCTGGCGCGAAACCTGGACTAAGGATCAC 262

Qy 241 CACTACTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTATGCATGCC 300
 |||||||

Db 263 CACTACTTAAATACTGCAAAATCTCAGCATTGGCTCTACTGAAAATGGTATGCATGCC 322

Qy	301	AGGTCA	GGAGGCA	ACTTGG	AAAGTGA	TGGGTTGATG	CTCGGAA	AGTCGACGGC	GAGACC	360	
Db	323	AGGTCA	GGAGGCA	ACTTGG	AAAGTGA	TGGGTTGATG	CTCGGAA	AGTCGACGGC	GAGACC	382	
Qy	361	ATGATCAT	CATGG	ACAGTT	CGCTTG	CCTGTAGAGGG	CACAGAA	ACTCGAG	TAAATGCT	420	
Db	383	ATGATCAT	CATGG	ACAGTT	CGCTTG	CCTGTAGAGGG	CACAGAA	ACTCGAG	TAAATGCT	442	
Qy	421	CAAGCTG	CTGCGT	ATGAGT	TATGGCTG	CATACATAGAAA	TGCCAAC	CAGGTTGGCC	GC	480	
Db	443	CAAGCTG	CTGCGT	ATGAGT	TATGGCTG	CATACATAGAAA	TGCCAAC	CAGGTTGGCC	GC	502	
Qy	481	CTTGAGA	ATGCA	ATCGGTTGG	TATCATAGCC	ACCCCTGGT	TATGGCTG	CTGGCT	CTCCGGG	540	
Db	503	CTTGAGA	ATGCA	ATCGGTTGG	TATCATAGCC	ACCCCTGGT	TATGGCTG	CTGGCT	CTCCGGG	562	
Qy	541	ATTGATG	TGTTAGT	TACACAGA	TGCTGAAC	CCAGCAG	TTCAAGA	ACCATTG	TAGCAGTGGT	600	
Db	563	ATTGATG	TGTTAGT	TACACAGA	TGCTGAAC	CCAGCAG	TTCAAGA	ACCATTG	TAGCAGTGGT	622	
Qy	601	ATTGATCC	AAACCAGA	ACAATCT	CTGCAGG	AAAAGTGA	ATCTGGCG	CCTT	AGGACATAT	660	
Db	623	ATTGATCC	AAACCAGA	ACAATCT	CTGCAGG	AAAAGTGA	ATCTGGCG	CCTT	AGGACATAT	682	
Qy	661	CCAAAGGG	CTACAAAC	CTCCTGATG	GAAGGAC	CTCTGAGT	ACCA	GACTATCCC	ACTTAAT	720	
Db	683	CCAAAGGG	CTACAAAC	CTCCTGATG	GAAGGAC	CTCTGAGT	ACCA	GACTATCCC	ACTTAAT	742	
Qy	721	AAAATAGA	AGATTG	CGTGC	ACTGCAA	ACAATATT	ATGCCT	TAGAAGT	CTCATATT	780	
Db	743	AAAATAGA	AGATTG	CGTGC	ACTGCAA	ACAATATT	ATGCCT	TAGAAGT	CTCATATT	802	
Qy	781	AAATCAT	CTTGG	ATCGTAA	ACTACTT	GAGCTT	TGTGA	ATAAA	ACTGGTGA	ATACC	840
Db	803	AAATCAT	CTTGG	ATCGTAA	ACTACTT	GAGCTT	TGTGA	ATAAA	ACTGGTGA	ATACC	862
Qy	841	CTGAGTT	CCTCTAG	CTTACTAAT	GCAGACTAC	ACACCAC	AGGCCAGG	TGTTG	ATTG	900	
Db	863	CTGAGTT	CCTCTAG	CTTACTAAT	GCAGACTAC	ACACCAC	AGGCCAGG	TGTTG	ATTG	922	
Qy	901	TCTGAGA	AGTTAGAGC	AGTCGG	AAAGCC	AACTGGGAC	GTGGCAG	TTCATG	TGGGCTTA	960	
Db	923	TCTGAGA	AGTTAGAGC	AGTCGG	AAAGCC	AACTGGGAC	GTGGCAG	TTCATG	TGGGCTTA	982	
Qy	961	GAAACACAT	GACCG	CAAGTC	GGAAAG	ACAAACT	TGCCAA	AGCTACTA	TAGAGACAG	GTAAA	1020
Db	983	GAAACACAT	GACCG	CAAGTC	GGAAAG	ACAAACT	TGCCAA	AGCTACTA	TAGAGACAG	GTAAA	1042

